University System of Maryland

The University of Texas System

Fzata, Inc.

Hua Yu

Hanping Feng

Yongrong Zhang

Zhilei Chen

Zhiyong Yang

Ana M Chamoun-Emanuelli

Yifan Zhang

Rudo Simeon

Zeyu Peng

In an embodiment, the present disclosure pertains to a method of treating or preventinginfections. In some embodiments, the method includes administering an antitoxin to a subject in need thereof. In some embodiments, the antitoxin includes a designed ankyrin repeat protein (DARPin). In an additional embodiments, the present disclosure pertains to a composition including an antitoxin for treating or preventinginfections. In some embodiments, the anti-toxin includes a DARPin. In some embodiments, the anti-toxin is a monomeric or dimeric DARPin for the neutralization oftoxin B (TcdB).

Protein inhibitors of clostridium difficile toxin b

Novel, antibody-based binding agents derived from camelid VH and human immunoglobulins are described. These binding agents recognize and bind with specificity totoxin A and/or toxin B and in some cases exhibit toxin neutralizing activity. These binding agents can be used to treat or prevent primary and recurrent CDI. The binding agents include humanized VH peptide monomers, linked groups of humanized VH peptide monomers, humanized VH peptide monomers joined to antibody Fc domains, and humanized VH peptide monomers joined to IgG antibodies.

Humanized tetra-specific octavalent antibody against clostridium difficile toxin A and B

Growing community of inventors

Columbia, MD, United States of America

Hua Yu